These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6531436)

  • 41. Monoamine oxidase-inhibiting properties of SR 95191, a new pyridazine derivative, in the rat: evidence for selective and reversible inhibition of monoamine oxidase type A in vivo but not in vitro.
    Kan JP; Steinberg R; Leclercq J; Worms P; Biziere K
    J Neurochem; 1988 Apr; 50(4):1137-44. PubMed ID: 3346672
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of diphenylhydantoin on brain 5-hydroxytryptamine metabolism and function.
    Green AR; Grahame-Smith DG
    Neuropharmacology; 1975 Feb; 14(2):107-13. PubMed ID: 1153078
    [No Abstract]   [Full Text] [Related]  

  • 43. Plasma 5-hydroxyindoleacetic acid as an indicator of monoamine oxidase-A inhibition in rat brain and peripheral tissues.
    Celada P; Artigas F
    J Neurochem; 1993 Dec; 61(6):2191-8. PubMed ID: 7504085
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of two substituted hydrazine monoamine oxidase (MAO) inhibitors on neurotransmitter amines, gamma-aminobutyric acid, and alanine in rat brain.
    Yamada N; Takahashi S; Todd KG; Baker GB; Paetsch PR
    J Pharm Sci; 1993 Sep; 82(9):934-7. PubMed ID: 7901387
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modification by monoamine oxidase inhibitors of the analgesic, hypothermic and toxic actions of morphine and pethidine in mice.
    Botting R; Bower S; Eason CT; Hutson PH; Wells L
    J Pharm Pharmacol; 1978 Jan; 30(1):36-40. PubMed ID: 22722
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recent studies on the MAO inhibitor phenelzine and its possible metabolites.
    McKenna KF; Baker GB; Coutts RT; Rauw G; Mozayani A; Danielson TJ
    J Neural Transm Suppl; 1990; 32():113-8. PubMed ID: 1982447
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential effects of monoamine oxidase inhibitors.
    Maickel RP; Rompalo AM; Cox RH
    Res Commun Chem Pathol Pharmacol; 1974 Aug; 8(4):727-30. PubMed ID: 4420181
    [No Abstract]   [Full Text] [Related]  

  • 48. Effect of decarboxylase inhibitors on brain p-tyrosine levels.
    Dyck LE
    Biochem Pharmacol; 1987 Apr; 36(8):1373-6. PubMed ID: 2885004
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stress reduces in vivo inhibition of monoamine oxidase by phenelzine in rat brain.
    Clow A; Glover V; Oxenkrug GF; Sandler M
    Neurosci Lett; 1989 Dec; 107(1-3):331-4. PubMed ID: 2616044
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of brain 5-hydroxytryptamine in the hyperactivity produced in rats by lithium and monoamine oxidase inhibition.
    Grahame-Smith DG; Green AR
    Br J Pharmacol; 1974 Sep; 52(1):19-26. PubMed ID: 4281339
    [TBL] [Abstract][Full Text] [Related]  

  • 51. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.
    Karoum F
    Br J Pharmacol; 1987 Feb; 90(2):335-45. PubMed ID: 3103805
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Monoamine oxidase inhibitors increase preferentially extracellular 5-hydroxytryptamine in the midbrain raphe nuclei. A brain microdialysis study in the awake rat.
    Celada P; Artigas F
    Naunyn Schmiedebergs Arch Pharmacol; 1993 Jun; 347(6):583-90. PubMed ID: 7689703
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characteristics and specificity of phenelzine and benserazide as inhibitors of benzylamine oxidase and monoamine oxidase.
    Andree TH; Clarke DE
    Biochem Pharmacol; 1982 Mar; 31(5):825-30. PubMed ID: 7082351
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The effect of monoamine oxidase inhibitors and reserpine on the gamma-aminobutyric acid content of the rat brain].
    Popov N; Matthies HJ
    Acta Biol Med Ger; 1967; 18(1):91-8. PubMed ID: 5587220
    [No Abstract]   [Full Text] [Related]  

  • 55. Serotonin-containing neurons in brain: depression of firing by monoamine oxidase inhibitors.
    Aghajanian GK; Graham AW; Sheard MH
    Science; 1970 Sep; 169(3950):1100-2. PubMed ID: 5449322
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of co-administration of a monoamine oxidase inhibitor and a 5-HT1A receptor antagonist on 5-hydroxytryptamine cell firing and release.
    Sharp T; Gartside SE; Umbers V
    Eur J Pharmacol; 1997 Feb; 320(1):15-9. PubMed ID: 9049597
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chronic MAO A and MAO B inhibition decreases the 5-HT1A receptor-mediated inhibition of forskolin-stimulated adenylate cyclase.
    Sleight AJ; Marsden CA; Palfreyman MG; Mir AK; Lovenberg W
    Eur J Pharmacol; 1988 Sep; 154(3):255-61. PubMed ID: 3234480
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of co-administration of antidepressants and monoamine oxidase inhibitors on 5-HT-related behavior in rats.
    Izumi T; Iwamoto N; Kitaichi Y; Kato A; Inoue T; Koyama T
    Eur J Pharmacol; 2007 Jun; 565(1-3):105-12. PubMed ID: 17400208
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dual action of antidepressant drugs (MAO inhibitors) on insulin release.
    Aleyassine H; Gardiner RJ
    Endocrinology; 1975 Mar; 96(3):702-10. PubMed ID: 1090438
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of monoamine oxidase inhibitors on the concentrations of dopamine and serotonin in the striatum of the cat with and without unilateral brainstem lesions.
    Singh P; Poirier LJ; Boucher R
    Can J Physiol Pharmacol; 1967 Sep; 45(5):897-904. PubMed ID: 6049616
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.